Filters
Custom request?
Type
Production region
Qualifications
Country of origin
Lornoxicam API Manufacturers & Suppliers
11 verified results
All Lornoxicam data. Full access. Full negotiation power
Commercial-scale Suppliers
Employees: 50
All certificates
Employees: 25
All certificates
Employees: 19
All certificates
All certificates
All certificates
All certificates
All certificates
All certificates
All certificates
All certificates
All certificates
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Lornoxicam | CAS No: 70374-39-9 | GMP-certified suppliers
A medication that provides analgesic and anti-inflammatory effects for managing acute mild to moderate pain and joint inflammation in rheumatic diseases.
Therapeutic categories
Primary indications
- For the treatment of acute mild to moderate pain, as well as pain and inflammation of the joints caused by certain types of rheumatic diseases
Product Snapshot
- Lornoxicam is available in multiple formulation types including oral tablets (film coated, effervescent, coated), capsules, granules for suspension, and parenteral forms such as injection solutions and lyophilized powders
- It is primarily indicated for the management of acute mild to moderate pain and inflammatory conditions associated with rheumatic diseases
- The product holds both approved and investigational status in key regulatory markets including FDA and EMA jurisdictions
Clinical Overview
Pharmacologically, lornoxicam exerts its effects through potent inhibition of the cyclooxygenase (COX) enzymes COX-1 and COX-2, which catalyze the conversion of arachidonic acid into prostaglandins and thromboxanes—key mediators of inflammation, pain, and fever. Unlike some other NSAIDs, lornoxicam’s inhibition of COX enzymes does not result in a compensatory increase in leukotriene production via the 5-lipoxygenase pathway. This selective inhibition is associated with a potentially reduced risk of adverse events linked to leukotriene-mediated effects.
The precise biochemical and cellular mechanisms underlying lornoxicam’s clinical activity remain not fully elucidated, though its action on prostaglandin and thromboxane synthesis is central to its analgesic and anti-inflammatory effects.
Pharmacokinetic data indicate that lornoxicam undergoes hepatic metabolism primarily via cytochrome P450 enzymes, including CYP2C9. The drug’s absorption, distribution, metabolism, and excretion (ADME) profiles support its clinical utility, though detailed parameters such as half-life and bioavailability are generally specified in product monographs.
Safety considerations include potential risks typical of non-selective NSAIDs, such as nephrotoxicity, hypertension, and altered potassium homeostasis. Lornoxicam is classified among agents that may cause hyperkalemia and hypertension and requires caution in patients with renal impairment or cardiovascular risk factors.
Notable uses of lornoxicam are in acute pain management and rheumatic conditions, administered as part of treatment regimens to reduce inflammation and improve patient comfort. Brand names and formulations are region-specific, with approved use documented primarily in Japan.
From an API procurement perspective, ensuring high purity and consistent quality of lornoxicam is critical. Given its metabolism via CYP2C9, controlling impurities that could affect hepatic metabolism is important. Sourcing should comply with international pharmaceutical standards and regulatory requirements, focusing on manufacturers with validated processes and appropriate analytical characterization to maintain safety and efficacy in finished pharmaceutical products.
Identification & chemistry
| Generic name | Lornoxicam |
|---|---|
| Molecule type | Small molecule |
| CAS | 70374-39-9 |
| UNII | ER09126G7A |
| DrugBank ID | DB06725 |
Pharmacology
| Summary | Lornoxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class that inhibits cyclooxygenase enzymes COX-1 and COX-2, reducing prostaglandin and thromboxane synthesis. This inhibition decreases inflammation, pain, fever, and swelling associated with rheumatic conditions and acute mild to moderate pain. Unlike some NSAIDs, lornoxicam does not promote increased leukotriene production, which may minimize certain adverse effects. |
|---|---|
| Mechanism of action | Like other NSAIDS, lornoxicam's anti-inflammatory and analgesic activity is related to its inhibitory action on prostaglandin and thromboxane synthesis through the inhibition of both COX-1 and COX-2. This leads to the reduction of inflammation, pain, fever, and swelling, which are mediated by prostaglandins. However, the exact mechanism of lornoxicam, like that of the other NSAIDs, has not been fully determined. |
| Pharmacodynamics | Lornoxicam is a non-steroidal anti-inflammatory drug (NSAID) that belongs to the oxicam class. As with other NSAIDS, lornoxicam is a potent inhibitor of the cyclooxgenase enzymes, which are responsible for catalyzing the formation of prostaglandins (act as messenger molecules in the process of inflammation) and thromboxane from arachidonic acid. Unlike some NSAIDS, lornoxicam's inhibition of cyclooxygenase does not lead to an increase in leukotriene formation, meaning that arachidonic acid is not moved to the 5-lipoxygenase cascade, resulting in the minimization of the risk of adverse events. |
Targets
| Target | Organism | Actions |
|---|---|---|
| Prostaglandin G/H synthase 1 | Humans | inhibitor |
| Prostaglandin G/H synthase 2 | Humans | inhibitor |
ADME / PK
| Absorption | Lornoxicam is absorbed rapidly and almost completely from the GI tract (90-100%). |
|---|---|
| Half-life | 3-5 hours |
| Protein binding | Lornoxicam is 99% bound to plasma proteins (almost exlusively to serum albumin). |
| Metabolism | Lornoxicam is metabolized completely by cyp 2C9 with the principal metabolite being 5'-hydroxy-lornoxicam and only negligible amounts of intact lornoxicam are excreted unchanged in the urine. Approximately 2/3 of the drug is eliminated via the liver and 1/3 via the kidneys in the active form. |
Formulation & handling
- Lornoxicam is a small molecule suitable for both oral and parenteral administration, including intravenous and intramuscular routes.
- The compound exhibits low water solubility, which necessitates formulation strategies to enhance bioavailability and solubility in injectable forms.
- As a chemically stable non-peptide, standard handling procedures apply without special sensitivity to food or biological degradation.
Regulatory status
Lornoxicam is a type of NSAIDs
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) are a widely used subcategory of pharmaceutical Active Pharmaceutical Ingredients (APIs). These medications are commonly prescribed for their analgesic (pain-relieving), anti-inflammatory, and antipyretic (fever-reducing) properties. NSAIDs work by inhibiting the production of certain enzymes called cyclooxygenases (COX), which play a crucial role in the synthesis of prostaglandins, substances that contribute to pain, inflammation, and fever.
These pharmaceutical APIs are available in various formulations, including tablets, capsules, creams, and gels, making them convenient for different administration routes. Some popular examples of NSAIDs include aspirin, ibuprofen, naproxen, and diclofenac.
NSAIDs are commonly used to treat a wide range of conditions such as arthritis, musculoskeletal injuries, dental pain, menstrual pain, and headaches. They are also effective in managing inflammatory conditions like rheumatoid arthritis and ankylosing spondylitis.
While NSAIDs are generally safe and effective when used as directed, they may have side effects. These can include gastrointestinal issues such as stomach ulcers or bleeding, cardiovascular risks, and kidney problems. Therefore, it is essential to follow the recommended dosage and consult with healthcare professionals to ensure proper and safe usage.
In conclusion, NSAIDs are a subcategory of pharmaceutical APIs that offer analgesic, anti-inflammatory, and antipyretic properties. Their versatility and effectiveness in treating various conditions make them widely prescribed medications. However, it is crucial to be aware of potential side effects and consult healthcare providers for appropriate usage.
Lornoxicam (NSAIDs), classified under Anti-inflammatory Agents
Anti-inflammatory agents are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) used to treat various inflammatory conditions. These agents play a vital role in alleviating pain, reducing swelling, and controlling inflammation in the body. They are widely employed in the management of diverse medical conditions, including arthritis, autoimmune disorders, asthma, and skin conditions like dermatitis.
Anti-inflammatory APIs primarily function by inhibiting the production of specific enzymes called cyclooxygenases (COX) and lipoxygenases (LOX). These enzymes are responsible for the synthesis of pro-inflammatory molecules known as prostaglandins and leukotrienes, respectively. By suppressing the activity of COX and LOX, anti-inflammatory agents effectively curtail the production of these inflammatory mediators, thereby mitigating inflammation.
Common examples of anti-inflammatory APIs include non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, aspirin, and naproxen. These agents exhibit analgesic, antipyretic, and anti-inflammatory properties. Another group of anti-inflammatory APIs includes corticosteroids, such as prednisone and dexamethasone, which are synthetic hormones that modulate the body's immune response to control inflammation.
In conclusion, anti-inflammatory agents are a vital category of pharmaceutical APIs widely used to manage inflammation-related disorders. They target enzymes involved in the synthesis of pro-inflammatory molecules, effectively reducing pain and swelling. NSAIDs and corticosteroids are commonly prescribed anti-inflammatory APIs due to their efficacy in controlling inflammation.
Lornoxicam API manufacturers & distributors
Compare qualified Lornoxicam API suppliers worldwide. We currently have 11 companies offering Lornoxicam API, with manufacturing taking place in 7 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| ACE Japan | Producer | Japan | Japan | CoA | 76 products |
| Apex Healthcare | Producer | India | India | CoA, WC | 9 products |
| AXXO GmbH | Distributor | Germany | European Union | CoA, GMP, GDP, MSDS, USDMF | 243 products |
| Edmond Pharma (Recipharm) | Producer | Italy | Italy | CoA, GMP | 20 products |
| Global Pharma Tek | Distributor | India | India | BSE/TSE, CoA, FDA, GMP, ISO9001, MSDS | 484 products |
| Humble Healthcaare | Producer | India | India | CoA | 30 products |
| Hwail Pharm | Producer | South Korea | South Korea | CoA, JDMF | 4 products |
| SETV Global | Producer | India | India | CoA, FDA, GMP | 515 products |
| Veeprho Group | Producer | Czech Republic | Czech Republic | CoA | 136 products |
| Zhejiang Zhenyuan | Producer | China | China | CoA, JDMF, WC | 3 products |
| Zydus Takeda Healthcare | Producer | India | India | CoA, WC | 7 products |
When sending a request, specify which Lornoxicam API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Lornoxicam API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
